2022 Satellite Symposia
Going the Distance in IBD: Ensuring Stability and Safety for Your Patients
Thursday, January 20, 7:30–8:30 p.m. EST
In partnership with GI Health Foundation
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
7:30–7:35 p.m. Welcome and Introductions
7:35–7:50 p.m. IBD Management in 2022 and Beyond – Jessica R. Allegretti, MD, MPH, FACG
7:50–8:05 p.m. Ensuring Durability in IBD – Maria T. Abreu, MD
8:05–8:20 p.m. Ensuring Safety in IBD – Anita Afzali, MD, MPH, FACG, AGAF
8:20–8:30 p.m. Panel Discussion Q&A
8:30 p.m. Meeting Adjourn
Getting a Better Sense of Sensitive Symptoms: What Matters Most to Patients With Ulcerative Colitis
Friday, January 21, 12:15–1:45 p.m. EST
In partnership with Answers in CME Inc.
This activity is supported by an educational grant from Lilly.
ENGAGE IN DISCUSSION WITH THE EXPERTS
Patients with ulcerative colitis are often hesitant to discuss symptoms such as bowel urgency with their provider, resulting in treatment gaps and poor quality of life. Join us as we discuss strategies to optimize patient-provider communication so that you can start these sensitive conversations with your patients with this challenging disease and help to improve outcomes.
- Gary R. Lichtenstein, MD, AGAF
- David T. Rubin, MD, AGAF
- Becky Johnson Rescola
Making the Switch from Biologics to Biosimilars in IBD: Knowledge Over Skepticism
Friday, January 21, 2022, 6–7:30 p.m. EST
In partnership with CME Outfitters, LLC
Supported by an educational grant from Amgen Inc.
The management of chronic autoimmune diseases such as inflammatory bowel disease (IBD) is often accomplished with the utilization of biologic agents. However, new biosimilars are emerging for the treatment of IBD. These biosimilars are molecules highly similar to approved biologic medicines and are comprehensively developed and rigorously tested to ensure that efficacy and safety are similar to the reference product. Unfortunately, both clinicians and patients lack knowledge of biosimilar efficacy and safety, which leads to fewer clinicians prescribing them and patients experiencing feelings of uncertainty and ungrounded negative perceptions toward receiving biosimilars.
This CME Outfitters symposium at the Crohn’s & Colitis Congress 2022 will feature an expert panel discussion that defines biosimilar terminology, presents clinical trial data and real-world evidence on the efficacy and safety of biosimilars, and details team-based strategies for enhancing patient-clinician shared decision-making (SDM) regarding the use of biosimilars.
- Learning the Landscape: Biosimilar vs. Biologics
- From Data to Practice: Examining the Efficacy and Safety of Biosimilars
- Engaging Shared Decision-Making: Every Conversation Counts
- Edward V. Loftus, Jr., MD, AGAF (moderator)
- Shubha Bhat, PharmD, MS, BCACP
- Christina Ha, MD, AGAF
The Crohn’s & Colitis Congress® will host 3 CME-accredited satellite symposia. All symposiums will occur during breakfast or lunch times.
Number of Live Symposia
Friday, Jan. 21
Friday, Jan. 21
Saturday, Jan. 22